Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.65 |
| ▸ | VNN1 | O95497 | 13/20 | 0.59 |
| ▸ | ECE1 | P42892 | 3/20 | 0.44 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pantothenic Acid, Racemic SCHEMBL27989847 | 1.00 | PTGS1 (0.65) | PTGS1KCNH2VNN1ECE1ZDHHC20 | |
| Pantothenic Acid SCHEMBL6472019 | 0.98 | PTGS1 (0.63) | PTGS1KCNH2VNN1ECE1ZDHHC20 | |
| Pantothenic Acid, Racemic SCHEMBL6472022 | 0.98 | PTGS1 (0.63) | PTGS1KCNH2VNN1ECE1ZDHHC20 | |
| Pantothenic Acid SCHEMBL29872649 | 0.98 | PTGS1 (0.67) | PTGS1KCNH2VNN1ECE1 | |
| Pantothenic Acid, Racemic SCHEMBL21114380 | 0.98 | PTGS1 (0.67) | PTGS1KCNH2VNN1ECE1 | |
| Pantothenic Acid SCHEMBL21547 | 0.98 | PTGS1 (0.67) | PTGS1KCNH2VNN1ECE1 | |
| Pantothenic Acid, Racemic SCHEMBL5437 | 0.98 | PTGS1 (0.67) | PTGS1KCNH2VNN1ECE1 | |
| Pantothenic Acid SCHEMBL5436 | 0.98 | PTGS1 (0.67) | PTGS1KCNH2VNN1ECE1 | |
| Pantothenic Acid SCHEMBL14126322 | 0.98 | PTGS1 (0.67) | PTGS1KCNH2VNN1ECE1 | |
| Pantothenic Acid SCHEMBL7016631 | 0.98 | PTGS1 (0.67) | PTGS1KCNH2VNN1ECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220249467-A1 | METHOD FOR IDENTIFYING TREATMENT OF INFECTIONS CAUSED BY PATHOGENS OF DIVERSE ORIGIN | SYSTAMEDIC INC. (US) | 2022-08-11 | — | — | US | claimed |
| US-20100069338-A1 | PHARMACEUTICAL COMPOSITIONS | YORK PHARMA PLC (GB) | 2010-03-18 | — | — | US | claimed |
| EP-2061428-A1 | IMPROVEMENTS IN PHARMACEUTICAL COMPOSITIONS | York Pharma PLC (GB) | 2009-05-27 | — | — | EP | claimed |
| WO-2008025837-A1 | IMPROVEMENTS IN PHARMACEUTICAL COMPOSITIONS | YORK PHARMA PLC (GB) | 2008-03-06 | — | — | WO | claimed |
| EP-3773467-B1 | ALL-IN-ONE LYOPHILIZED MULTIVITAMIN EMULSION FOR PARENTERAL APPLICATION | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2024-10-16 | — | — | EP | disclosed |
| US-11975102-B2 | All-in-one lyophilized multivitamin emulsion for parenteral application | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2024-05-07 | — | — | US | disclosed |
| CN-110573142-B | All-in-one lyophilized multivitamin emulsion for parenteral use | 费森尤斯卡比德国有限公司 | 2024-01-16 | — | — | CN | disclosed |
| WO-2023277084-A1 | COMPOSITION FOR ORAL CAVITY | ライオン株式会社 | 2023-01-05 | — | — | WO | disclosed |
| US-20220249467-A1 | METHOD FOR IDENTIFYING TREATMENT OF INFECTIONS CAUSED BY PATHOGENS OF DIVERSE ORIGIN | SYSTAMEDIC INC. (US) | 2022-08-11 | — | — | US | disclosed |
| EP-3773467-A1 | ALL-IN-ONE LYOPHILIZED MULTIVITAMIN EMULSION FOR PARENTERAL APPLICATION | Fresenius Kabi Deutschland GmbH (DE) | 2021-02-17 | — | — | EP | disclosed |
| US-20200297638-A1 | All-in-one lyophilized multivitamin emulsion for parenteral application | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2020-09-24 | — | — | US | disclosed |
| CN-110573142-A | all-in-one freeze-dried composite vitamin emulsion for parenteral application | 费森尤斯卡比德国有限公司 | 2019-12-13 | — | — | CN | disclosed |
| US-20120273374-A1 | CORROSION INHIBITION OF HYPOCHLORITE SOLUTIONS IN SATURATED WIPES | ECOLAB USA INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120241679-A1 | CORROSION INHIBITION OF HYPOCHLORITE SOLUTIONS | ECOLAB USA INC. (US) | 2012-09-27 | — | — | US | disclosed |
| WO-2012085830-A2 | CORROSION INHIBITION OF HYPOCHLORITE SOLUTIONS USING POLYACRYLATE AND Ca, Zn AND Ca, SUGAR ACIDS AND Ca | ECOLAB USA INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| US-8114343-B1 | Corrosion inhibition of hypochlorite solutions using Zn and Ca | Ecolab USA, Inc. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20100069338-A1 | PHARMACEUTICAL COMPOSITIONS | YORK PHARMA PLC (GB) | 2010-03-18 | — | — | US | disclosed |
| EP-2061428-A1 | IMPROVEMENTS IN PHARMACEUTICAL COMPOSITIONS | York Pharma PLC (GB) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008025837-A1 | IMPROVEMENTS IN PHARMACEUTICAL COMPOSITIONS | YORK PHARMA PLC (GB) | 2008-03-06 | — | — | WO | disclosed |
| US-5661177-A | TOPICAL APPLICATION OF ANHYDROUS OR HYDRATED ZINC SALT OF CYSTEIC ACID | CHIMIE ET BIOLOGIE (FR) | 1997-08-26 | — | — | US | disclosed |